Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arne Blickle

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Nuclear Medicine and Molecular Imaging|February 10, 2026
Auger Emitting [<sup>161</sup>Tb]Tb-PSMA-617 Radioligand Therapy in mCRPC with Peritoneal CarcinomatosisFlorian Rosar, Arne Blickle, Moritz B Bastian, et al.
EJNMMI Research|March 16, 2026
Outcome and safety of single-dose docetaxel-augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: preliminary evidence from a pilot experienceNiklas Ebert, Florian Rosar, Caroline Burgard, et al.
Frontiers in Medicine|February 1, 2024
Change of glucometabolic activity per PSMA expression predicts survival in mCRPC patients non-responding to PSMA radioligand therapy: introducing a novel dual imaging biomarkerCaroline Burgard, Jakob Engler, Arne Blickle, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 27, 2023
Change in total lesion PSMA (TLP) during [<sup>177</sup>Lu]Lu-PSMA-617 radioligand therapy predicts overall survival in patients with mCRPC: monocentric evaluation of a prospective registryCaroline Burgard, Connor Hein, Arne Blickle, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|July 3, 2025
Tumor sink effect in PSMA-targeted theranostics: intra-patient evaluation of a cohort receiving 225Ac/177Lu-PSMA tandem radioligand therapyCaroline Burgard, Marie D Muenzenberg, Arne Blickle, et al.
Clinical Nuclear Medicine|May 21, 2024
225 Ac-PSMA-617 Augmentation in High-Risk mCRPC Undergoing 177 Lu-PSMA-617 Radioligand Therapy : Pilot Experience From a Prospective RegistryFlorian Rosar, Caroline Burgard, Luna Vanessa Rohloff, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 15, 2024
Efficacy and safety of rechallenge [<sup>177</sup>Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study)Florian Rosar, Joelle Schuler, Caroline Burgard, et al.
Theranostics|March 20, 2024
[<sup>161</sup>Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [<sup>177</sup>Lu]Lu-PSMA-617Andrea Schaefer-Schuler, Caroline Burgard, Arne Blickle, et al.
Theranostics|September 18, 2025
Pilot experience of [<sup>161</sup>Tb]Tb-PSMA-617 RLT in mCRPC patients after conventional PSMA RLT within a prospective registryFlorian Rosar, Caroline Burgard, Christine Petrescu, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 3, 2024
Safety of PSMA radioligand therapy in mCRPC patients with preexisting moderate to severe thrombocytopeniaMoritz B Bastian, Maike Sieben, Arne Blickle, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Nuclear Medicine and Molecular Imaging|February 10, 2026
Auger Emitting [<sup>161</sup>Tb]Tb-PSMA-617 Radioligand Therapy in mCRPC with Peritoneal CarcinomatosisFlorian Rosar, Arne Blickle, Moritz B Bastian, et al.
EJNMMI Research|March 16, 2026
Outcome and safety of single-dose docetaxel-augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: preliminary evidence from a pilot experienceNiklas Ebert, Florian Rosar, Caroline Burgard, et al.
Frontiers in Medicine|February 1, 2024
Change of glucometabolic activity per PSMA expression predicts survival in mCRPC patients non-responding to PSMA radioligand therapy: introducing a novel dual imaging biomarkerCaroline Burgard, Jakob Engler, Arne Blickle, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 27, 2023
Change in total lesion PSMA (TLP) during [<sup>177</sup>Lu]Lu-PSMA-617 radioligand therapy predicts overall survival in patients with mCRPC: monocentric evaluation of a prospective registryCaroline Burgard, Connor Hein, Arne Blickle, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|July 3, 2025
Tumor sink effect in PSMA-targeted theranostics: intra-patient evaluation of a cohort receiving 225Ac/177Lu-PSMA tandem radioligand therapyCaroline Burgard, Marie D Muenzenberg, Arne Blickle, et al.
Clinical Nuclear Medicine|May 21, 2024
225 Ac-PSMA-617 Augmentation in High-Risk mCRPC Undergoing 177 Lu-PSMA-617 Radioligand Therapy : Pilot Experience From a Prospective RegistryFlorian Rosar, Caroline Burgard, Luna Vanessa Rohloff, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 15, 2024
Efficacy and safety of rechallenge [<sup>177</sup>Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study)Florian Rosar, Joelle Schuler, Caroline Burgard, et al.
Theranostics|March 20, 2024
[<sup>161</sup>Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [<sup>177</sup>Lu]Lu-PSMA-617Andrea Schaefer-Schuler, Caroline Burgard, Arne Blickle, et al.
Theranostics|September 18, 2025
Pilot experience of [<sup>161</sup>Tb]Tb-PSMA-617 RLT in mCRPC patients after conventional PSMA RLT within a prospective registryFlorian Rosar, Caroline Burgard, Christine Petrescu, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 3, 2024
Safety of PSMA radioligand therapy in mCRPC patients with preexisting moderate to severe thrombocytopeniaMoritz B Bastian, Maike Sieben, Arne Blickle, et al.
Pageof 4